Cervical Cancer Indications
On November 19, 2021 , the Respacio® radiotherapy protection hydrogel clinical trial investigator meeting was successfully held, and the international innovative hydrogel for cervical cancer radiotherapy protection officially started the registration clinical trial.
In June 2022 , Respacio® radiotherapy protection hydrogel successfully completed the first phase of the registration clinical study at Peking Union Medical College Hospital, with several patients enrolled, and the hydrogel injection and implantation surgery was a complete success.
On April 7, 2023 , Reunion's domestic Respacio® radiotherapy protection hydrogel was unveiled at the multidisciplinary seminar of the China Radiation Intestinal Injury Research Collaborative Group.
In June 2023 , the registration clinical trial of Respacio® radiotherapy protection hydrogel for cervical cancer indications, led by Peking Union Medical College Hospital, has successfully completed the enrollment of all cases.
On September 16, 2023 , Reunion's Respacio® radiotherapy protection hydrogel was unveiled at the 5th Academic Conference of the Brachytherapy Professional Committee of the Chinese Anti-Cancer Association.
On May 24, 2024 , Reunion successfully held the closing meeting of the registered clinical project of Respacio ® radiotherapy protection hydrogel in Jinan.
On May 25, 2024 , Reunion's Respacio ® radiotherapy protection hydrogel appeared at the 6th National Academic Conference of the Brachytherapy Committee of the Chinese Anti-Cancer Association.
Product usage diagram
Contact Us
Telephone: 021-51592768
E-mail: cs@reunionmed.com
Address: Floor 2, Building 7, 1630 Yecheng Road, Jiading District, Shanghai
Scan QR Code